Lipitor (Pfizer)
Patent expiry: November 2011

2012 sales: $3.948 billion
2011 sales: $9.577 billion
Change: (59%)

It is a bit of a headshaker that Lipitor placed third in cardio sales, given all of the publicity about the patent loss on the world's most profitable drug. Of course, the nearly 60% drop in sales is pretty incredible and was the key reason Pfizer's ($PFE) U.S. revenues cratered by 14% and international revenues fell 6% in 2012. Still, Lipitor remained among Pfizer's 5 top-selling products, a reflection of the enormous footprint it had laid down on the world.  

The impact of the loss has been so great that it has led CEO Ian Read to a complete resculpting of the pharma giant. Read agreed last year to sell Pfizer's nutrition business to Nestle for $11.85 billion. The animal health business, which had been part of Pfizer for 65 years, was spun off into Zoetis ($ZTS) in February. About 20% of the company was sold in an IPO and Pfizer kept the rest.

Special Reports: Lipitor - The 15 best-selling drugs of 2012

For more:
Pfizer's Zoetis spinoff outshines drug biz, at least for a day
Fighting the $9B ghost of Lipitor past, Pfizer points to new drugs
Pfizer gets $11.85B in nutrition sale to Nestlé


Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.